Loading...
•
Mar 31, 2021
Enanta Pharmaceuticals Q2 2021 Earnings Report
Enanta Pharmaceuticals reported financial results for the fiscal second quarter ended March 31, 2021.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $20.1 million for the quarter, primarily from royalty revenue. The company's net loss was $22.0 million, or $1.09 per diluted common share. Cash and marketable securities totaled $400.4 million at the end of the quarter.
Reported positive data from a Phase 1b study of EDP-514 in NUC-Suppressed Chronic Hepatitis B Virus (HBV) Patients Supporting Once Daily Dosing and Combination Approach.
On track to report preliminary data from a Phase 1b Study of EDP-514 in Viremic Chronic HBV Patients in Q2 2021 and to Initiate a Phase 1 Study of EDP-721 in Mid-2021.
IND-Enabling Studies of a Lead Oral Protease Inhibitor Specifically Designed for SARS-CoV-2 Expected to Begin in Q2 2021.
Initiated RSVPEDs, a Phase 2 Study of EDP-938 in Pediatric Patients with Respiratory Syncytial Virus (RSV) Infection.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.